Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pneumonia IV: Management01:28

Pneumonia IV: Management

317
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
317
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.0K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.0K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

200
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
200
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

188
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
188
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

170
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
170
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

129
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
129

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Respiratory evolution after antenatal betamethasone dose reduction in very preterm neonates: a post hoc analysis of the BETADOSE trial.

European journal of pediatrics·2026
Same author

Diagnostic accuracy of rapid antigen detection tests for group A Streptococcus in children with extrapharyngeal infections: systematic review and meta-analysis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Knowledge of maternity caregivers on vaccination BCG recommendations and circuits.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

Diagnostic Accuracy Studies: Sensitivity, Specificity, and Beyond.

Journal of periodontal research·2026
Same author

Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants.

Pediatric pulmonology·2026
Same author

Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial.

American journal of hematology·2026

相关实验视频

Updated: Jun 21, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

尼尔西维玛和RSV支气管炎的住院治疗

Zein Assad1, Anne-Sophie Romain1, Camille Aupiais1

  • 1From the Department of General Pediatrics, Pediatric Infectious Disease, and Internal Medicine (Z.A., A.G., N.O.), Centre d'Investigations Cliniques, INSERM Unité 1426 (Z.V.), the Pediatric Intensive Care Unit (M. Levy, P.S.), the Pediatric Emergency Department (L.L.), the Department of Microbiology (M.G.-M.), the Neonatal Intensive Care Unit (V.B.), and the Unit of Clinical Epidemiology, INSERM Unité 1123 and Epidémiologie Clinique du Centre d'Investigation Clinique 1426 (K.D., O.A.), Robert-Debré University Hospital, Paris Cité University (Z.A., C.S., A.G., Z.V., M.B., J.F.C., J.T., M.L., P.S., L.L., M.G.-M., V.B., K.D., O.A.), the Departments of General Pediatrics (A.-S.R., M. Lorrot, C.F.) and Pediatric Pulmonology (A.-S.R., M. Lorrot), Armand Trousseau University Hospital, Sorbonne University (A.-S.R., M. Lorrot), the Pediatric Emergency Department (C.S.), the Pediatric Intensive Care Unit (M.B.), and the Department of General Pediatrics and Pediatric Infectious Diseases (C.S., J.F.C., J.T.), Necker-Enfants Malades University Hospital, Saint-Antoine Research Center, INSERM Unité Mixte de Recherche (UMR) S938 (H.C., B.P.), and Assistance Publique-Hôpitaux de Paris (AP-HP), Infection, Antimicrobials, Modeling, and Evolution (IAME) Research Unit, INSERM UMR 1137 (Z.A., L.L., M.G.-M., N.O.), Épidémiologie Clinique et Évaluation Économique Appliqué aux Populations Vulnérables, INSERM UMR 1123 (C.A.), the Center of Research in Epidemiology and Statistics, INSERM UMR 1153 (J.F.C.), and Biodiversity and Epidemiology of Bacterial Pathogens Research Unit, Institut Pasteur (J.T.), Paris Cité University, Paris, Groupe de Pathologie Infectieuse Pédiatrique, Nice (Z.A., M. Lorrot, R.C., C.L., N.O.), the Pediatric Emergency Department (C.A.) and the Department of General Pediatrics (L.P., C.F.D.), Jean Verdier University Hospital, AP-HP de Paris, Bondy, the Department of General Pediatrics, Centre Hospitalier Intercommunal de Créteil (M.S., C.J.), Association Clinique et Thérapeutique Infantile du Val-de-Marne France (R.C., C.L.), Institut Mondor de Recherche Biomédicale-Groupe de Recherche Clinique Groupe d'Étude des Maladies Infectieuses Néonatales et Infantiles, Université Paris Est (R.C., C.L., C.J.), and the Clinical Research Center (M.M.E.H., C.J.) and the Neonatal Intensive Care Unit (X.D.), Centre Hospitalier Intercommunal de Créteil, Université Paris Est Créteil, Faculté de Santé de Créteil, Créteil, Association Française de Pédiatrie Ambulatoire, Orleans (R.C., C.L.), and the Departments of Pediatric Pulmonology and Allergology (G.L., N.C.) and General Pediatrics (B.H., O.M., C.B.), Children's Hospital, Toulouse University Hospital, Toulouse - all in France; and the Department of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (F.A.).

The New England journal of medicine
|July 10, 2024
PubMed
概括

尼尔西维玛能有效地减少婴儿因呼吸道综合体病毒 (RSV) 相关的支气管炎住院. 这项实践研究表明,尼尔塞维马布治疗显著降低了幼儿严重RSV疾病的风险.

更多相关视频

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.6K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

相关实验视频

Last Updated: Jun 21, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.6K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

科学领域:

  • 儿科 儿科 儿科
  • 传染性疾病 传染性疾病
  • 免疫学 免疫学 免疫学

背景情况:

  • 呼吸道综合体病毒 (RSV) 是婴儿支气管炎的主要原因,每年导致全球数百万人住院治疗.
  • 长效单克隆抗体Nirsevimab针对RSV,但其在许可后的实际有效性需要评估.

研究的目的:

  • 评估nirsevimab在预防12个月以下婴儿因RSV相关支气管炎住院治疗中的实际有效性.
  • 分析nirsevimab对重症结局的影响,如重症监护和呼吸系统支持.

主要方法:

  • 进行了一项前性,多中心,匹配的病例控制研究.
  • 由于RSV支气管炎住院的婴儿 (病例) 与因其他疾病住院的婴儿 (对照组) 根据年龄,访问日期和研究中心相匹配,比率为2:1.
  • 使用多变量条件逻辑回归来计算nirsevimab的有效性,并对混因素进行调整.

主要成果:

  • 这项研究包括1035名婴儿 (690例,345例对照).
  • 尼尔塞维马布治疗显示,针对RSV相关的支气管炎住院治疗的调整后有效率为83.0% (95% CI,73.4-89.2).
  • 针对重症监护和呼吸器支持的有效性分别为69.6% (95% CI,42.9-83.8) 和67.2% (95% CI,38.6-82.5).

结论:

  • 在现实环境中,nirsevimab疗法有效降低婴儿RSV相关支气管炎住院的风险.
  • 这些发现支持nirsevimab在保护幼儿免受严重RSV疾病方面的作用.